Skip to main content
. Author manuscript; available in PMC: 2022 Sep 19.
Published in final edited form as: Mol Cancer Ther. 2021 Feb 3;20(4):665–675. doi: 10.1158/1535-7163.MCT-20-0386

Figure 6.

Figure 6.

ONC201 inhibits tumor growth. A, B) TT and MZCRC1 cells were injected into nude mice (n=8) and were treated with ONC201 (120 mg/kg/week, oral gavage) or vehicle for 8 weeks, and tumor growth was measured every week for 8 weeks. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 by the Holm-Sidak method. C) Western blot analysis of the MTC xenograft tumor tissues from the vehicle-treated or ONC201-treated mice with the indicated antibodies. D) Densitometric quantification of RET and VEGFR2 and IGFBP2 relative to vinculin in control and ONC201 treated tumors (unpaired t-test). E) Immunohistologic analysis of the expression of proliferation marker Ki67 quantified as a percentage of Ki67-positive cells for each xenograft tumor (n=6), magnification 20x. F) Immunohistologic analysis of the expression of IGFBP2, quantified as H-score (% staining × intensity) for each xenograft tumor (n=6), magnification 20x. G) Immunohistologic analysis of the expression of angiogenesis marker CD31, quantified as the number of vessels per field in each xenograft tumor (n=6), magnification 20x.